Evalyn Kennedy
Family · Loysburg, PANPI 1275059461
Payments from drug & device makers
Across 417 payments — averaging $17.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$961
- Lilly USA, LLC$880
- Novo Nordisk$837
- AbbVie$608
- Pfizer$587
- AstraZeneca$577
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,13799%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 64 | $961 |
| Lilly USA, LLC | 52 | $880 |
| Novo Nordisk | 46 | $837 |
| AbbVie | 36 | $608 |
| Pfizer | 40 | $587 |
| AstraZeneca(2 entities) | 31 | $577 |
| Boehringer Ingelheim | 24 | $484 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 22 | $374 |
| Amgen | 19 | $363 |
| Amarin Pharma, Inc. | 13 | $213 |
| Bayer | 10 | $190 |
| Kowa Pharmaceuticals America, Inc. | 10 | $182 |
| Merck | 8 | $138 |
| Astellas Pharma US Inc | 7 | $134 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $78 |
| Phathom Pharmaceuticals, Inc. | 4 | $76 |
| Esperion Therapeutics, Inc. | 5 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Biohaven Pharmaceuticals, Inc. | 3 | $59 |
| Exact Sciences | 3 | $54 |
| Johnson & Johnson | 2 | $45 |
| Paratek Pharmaceuticals, Inc. | 2 | $44 |
| Novartis | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Abbott | 2 | $30 |
| Ardelyx, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $22 |
How this compares
$7,182 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 112 | $120,680 |
| OzempicSemaglutide | 85 | $105,018 |
| FarxigaDapagliflozin Propanediol | 80 | $88,925 |
| EliquisApixaban | 66 | $70,554 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $47,060 |
| MounjaroTirzepatide | 19 | $33,640 |
| TrulicityDulaglutide | 26 | $32,096 |
| RybelsusSemaglutide | 29 | $30,762 |
| TradjentaLinagliptin | 32 | $27,382 |
| ProliaDenosumab | 15 | $24,873 |
| MyrbetriqMirabegron | 28 | $22,890 |
| DapagliflozinDapagliflozin Propanediol | 20 | $18,652 |
| WegovySemaglutide | 14 | $17,788 |
| KerendiaFinerenone | 14 | $13,681 |
| XareltoRivaroxaban | 13 | $11,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $837 | $153,568128 claims |
| Boehringer IngelheimJardiance, Tradjenta | $484 | $148,062144 claims |
| AstraZenecaFarxiga | $577 | $88,92580 claims |
| PfizerEliquis | $587 | $70,55466 claims |
| Lilly USA, LLCMounjaro, Trulicity | $880 | $65,73645 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $961 | $64,504119 claims |
| AmgenProlia | $363 | $24,87315 claims |
| Astellas Pharma US IncMyrbetriq | $134 | $22,89028 claims |
| BayerKerendia | $190 | $13,68114 claims |
| Johnson & JohnsonXarelto | $45 | $11,63413 claims |
| AbbVieSynthroid | $608 | $2,16829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Loysburg
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.